Oppenheimer Asset Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2023
Q2 | – | Sell |
-9,579
| Closed | -$391K | – | 1152 |
|
2023
Q1 | $391K | Buy |
9,579
+944
| +11% | +$38.5K | 0.01% | 903 |
|
2022
Q4 | $333K | Sell |
8,635
-3,968
| -31% | -$153K | 0.01% | 941 |
|
2022
Q3 | $670K | Sell |
12,603
-1,338
| -10% | -$71.1K | 0.01% | 765 |
|
2022
Q2 | $813K | Sell |
13,941
-5,413
| -28% | -$316K | 0.01% | 730 |
|
2022
Q1 | $1.48M | Sell |
19,354
-690
| -3% | -$52.7K | 0.02% | 630 |
|
2021
Q4 | $1.21M | Sell |
20,044
-1,237
| -6% | -$74.4K | 0.02% | 721 |
|
2021
Q3 | $1.19M | Buy |
21,281
+1,844
| +9% | +$103K | 0.02% | 689 |
|
2021
Q2 | $1.18M | Buy |
19,437
+3,521
| +22% | +$214K | 0.02% | 698 |
|
2021
Q1 | $1.12M | Buy |
15,916
+3,302
| +26% | +$232K | 0.02% | 688 |
|
2020
Q4 | $755K | Buy |
12,614
+4,949
| +65% | +$296K | 0.01% | 775 |
|
2020
Q3 | $461K | Buy |
7,665
+3,060
| +66% | +$184K | 0.01% | 836 |
|
2020
Q2 | $242K | Buy |
4,605
+3,114
| +209% | +$164K | 0.01% | 985 |
|
2020
Q1 | $50K | Buy |
1,491
+897
| +151% | +$30.1K | ﹤0.01% | 1262 |
|
2019
Q4 | $27K | Sell |
594
-123
| -17% | -$5.59K | ﹤0.01% | 1421 |
|
2019
Q3 | $27K | Sell |
717
-7,049
| -91% | -$265K | ﹤0.01% | 1426 |
|
2019
Q2 | $338K | Sell |
7,766
-175
| -2% | -$7.62K | 0.01% | 925 |
|
2019
Q1 | $302K | Buy |
7,941
+188
| +2% | +$7.15K | 0.01% | 937 |
|
2018
Q4 | $333K | Sell |
7,753
-1,410
| -15% | -$60.6K | 0.01% | 867 |
|
2018
Q3 | $450K | Sell |
9,163
-98
| -1% | -$4.81K | 0.01% | 848 |
|
2018
Q2 | $297K | Sell |
9,261
-2,601
| -22% | -$83.4K | 0.01% | 950 |
|
2018
Q1 | $370K | Buy |
11,862
+4,487
| +61% | +$140K | 0.01% | 865 |
|
2017
Q4 | $277K | Hold |
7,375
| – | – | 0.01% | 950 |
|
2017
Q3 | $277K | Buy |
7,375
+4,976
| +207% | +$187K | 0.01% | 954 |
|
2017
Q2 | $114K | Buy |
+2,399
| New | +$114K | ﹤0.01% | 1161 |
|